{"entity":{"id":"ctong-2201","kind":"trial","name":"CTONG 2201","aka":["CTONG2201"],"tldr":"A Chinese lung cancer study following people whose blood tests stayed negative after surgery, to see whether they can safely skip further treatment.","summary":"CTONG 2201 (NCT05457049) is a prospective, multicentre, single-arm observational study by the Chinese Thoracic Oncology Group. Patients with resected stage IB to IIIA non-small cell lung cancer whose residual disease tests are undetectable at the landmark and over time are followed closely; the primary endpoint is two-year disease-free survival. The registry lists 180 planned participants and an estimated primary completion in December 2026.","status":"recruiting","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT05457049","url":"https://clinicaltrials.gov/study/NCT05457049"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["mrd-testing"],"targets":[],"drugs":[],"companies":["ctong"],"institutions":[],"pathways":[],"terms":["mrd","ctdna","tumour-informed-assay"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05457049","phase":"observational","setting":"Completely resected stage IB to IIIA non-small cell lung cancer with landmark and longitudinal undetectable residual disease: close surveillance without adjuvant therapy","sponsor":"Guangdong Association of Clinical Trials","started":"2022-08-01","startedType":"actual","enrolled":180,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/ctong-2201/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"company":[{"id":"ctong","kind":"company","name":"Chinese Thoracic Oncology Group","route":"/companies/ctong/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"},{"id":"tumour-informed-assay","kind":"term","name":"Tumour-informed versus tumour-naive ctDNA assays","route":"/terms/tumour-informed-assay/"}]}}